These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6778799)

  • 21. Intrathoracic platelet accumulation in the guinea-pig induced by intravenous administration of arachidonic acid--effect of cyclooxygenase and thromboxane synthetase inhibitors.
    Barrett PA; Butler KD; Shand RA; Wallis RB
    Thromb Haemost; 1986 Dec; 56(3):311-7. PubMed ID: 3105107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cyclooxygenase inhibition on platelet-vessel wall interaction.
    Bourgain RH; Andries R; Maes L
    Haemostasis; 1983; 13(2):102-8. PubMed ID: 6409710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production.
    Jørgensen KA; Stoffersen E
    Pharmacol Res Commun; 1981 Jun; 13(6):579-86. PubMed ID: 6794043
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of dazoxiben on platelet-vessel wall interaction.
    Davies JA; Menys VC
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):45S-46S. PubMed ID: 6681703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Localization of prostacyclin activity in the rabbit aorta].
    Herman AG
    Verh K Acad Geneeskd Belg; 1984; 46(4):233-52. PubMed ID: 6393629
    [No Abstract]   [Full Text] [Related]  

  • 26. Contraction of the canine basilar artery following linoleic, arachidonid 13-hydroperoxylinoleic, or 15-hydroperoxyarachidonic acid.
    Koide T; Noda Y; Hata S; Sugioka K; Kobayashi S; Nakano M
    Proc Soc Exp Biol Med; 1981 Dec; 168(3):399-402. PubMed ID: 6798575
    [No Abstract]   [Full Text] [Related]  

  • 27. The role of prostaglandins in platelet-vessel wall interaction.
    Bourgain RH; Andries R; Finne E
    Arch Int Pharmacodyn Ther; 1979 May; 239(1):161-3. PubMed ID: 384949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low density lipoproteins (LDL) are carriers for lipid peroxides and inhibit prostacyclin (PGI2) biosynthesis in arteries.
    Szczeklik A; Gryglewski RJ
    Artery; 1980; 7(6):488-95. PubMed ID: 7016082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mepindolol protection of prostacyclin formation. Subsequent increase in arachidonic acid-induced prostacyclin release in isolated guinea pig heart.
    Kahlen T; Schrör K
    Eur J Pharmacol; 1982 Aug; 82(1-2):81-4. PubMed ID: 6813128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of arachidonic acid metabolites to atherosclerosis.
    Dembińska-Kieć A; Gryglewski RJ
    Wien Klin Wochenschr; 1986 Apr; 98(7):198-206. PubMed ID: 3010578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of ibuprofen dose on rabbit platelet aggregation and aortic pgi2 synthesis.
    Adesuyi SA; Ellis EF
    Thromb Res; 1982 Nov; 28(4):581-5. PubMed ID: 6761894
    [No Abstract]   [Full Text] [Related]  

  • 32. A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation.
    Gryglewski RJ; Dembínska-Kieć A; Korbut R
    Acta Biol Med Ger; 1978; 37(5-6):715-23. PubMed ID: 369254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet hypersensitivity induced by 1-chloro-2, 4-dinitrobenzene, hydroperoxides and inhibition of lipoxygenase.
    Hill TD; White JG; Rao GH
    Thromb Res; 1989 Mar; 53(5):447-55. PubMed ID: 2499941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent constriction of cat coronary arteries by hydroperoxides of arachidonic acid and its blockade by anti-inflammatory agents.
    Trachte GJ; Lefer AM; Aharony D; Smith JB
    Prostaglandins; 1979 Dec; 18(6):909-14. PubMed ID: 547310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of prostaglandin biochemical pathway in platelet-vessel wall interaction and local thrombosis.
    Bourgain RH; Andries R; Six F
    Haemostasis; 1982; 11(3):133-8. PubMed ID: 7095602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981.
    Vane JR
    J Endocrinol; 1982 Nov; 95(2):3P-43P. PubMed ID: 6816886
    [No Abstract]   [Full Text] [Related]  

  • 37. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium.
    Moncada S; Herman AG; Higgs EA; Vane JR
    Thromb Res; 1977 Sep; 11(3):323-44. PubMed ID: 335560
    [No Abstract]   [Full Text] [Related]  

  • 38. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
    Aiken JW; Shebuski RJ; Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
    [No Abstract]   [Full Text] [Related]  

  • 39. Platelet interaction with vascular smooth muscle in synthesis of prostacyclin.
    Hechtman DH; Kroll MH; Gimbrone MA; Schafer AI
    Am J Physiol; 1991 May; 260(5 Pt 2):H1544-51. PubMed ID: 1903602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The modification of the biosynthesis and effect of thromboxane A2 and prostacyclin by trapidil (Rocornal)].
    Block HU; Heinroth I; Giessler C; Pönicke K; Mentz P; Zehl U; Rettkowski W; Dunemann A; Förster W
    Biomed Biochim Acta; 1983; 42(2-3):283-99. PubMed ID: 6411078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.